Dr. Lindsay A. Rein

I have the privilege of caring for patients with various myeloproliferative neoplasms including, polycythemia vera, essential thrombocytosis, primary myelofibrosis, systemic mastocytosis, and chronic myeloid leukemia. My goal is to provide the best possible care for each individual patient in an era where the number of therapeutic options for patients with myeloproliferative neoplasms is rapidly expanding. As a clinical investigator leading several clinical studies in both early and late stages of development, I strive to offer patients access to investigational agents with novel mechanisms of action via participation in clinical trials. I believe that every patient has a unique diagnosis and personal experience with their cancer. I aim to consider the disease, the patient and individual care goals in partnering with patients to develop and implement personalized treatment plans.

Dr. Rein is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Systemic Mastocytosis, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Dr. Rein is board certified in American Board Of Internal Med, Medical Oncology and American Board Of Internal Med, Hematology. She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.